Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Novo GLP-1 drug shows less lean mass loss than rivals, study says Eli Lilly's LLY.N GLP-1 drug tirzepatide yields greater weight loss on average than Novo Nordisk's NOVOb.CO semaglutide, but at a greater expense to muscles and connective tissues, according to a study published this week ahead of peer review
Rt mong nhn c s ng h v tn nhim lu di ca qu khch hng
Novo Nordisk investor relations
(2023, July 5)
US$ 26.44
US$ 28.08
US$ 27.92
US$ 22.43
